ArticleProceedings of the National Academy of Sciences of the United States of America2017
Angptl4 does not control hyperglucagonemia or α-cell hyperplasia following glucagon receptor inhibition.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 20 citations in OpenAlex.
- Advances in basic research on glucagon and alpha cells.Diabetology international · 2024Review
- Establishment of a Mitochondrial Metabolism-Related Diagnostic Model in Schizophrenia Based on LASSO Algorithm.Psychiatry investigation · 2024Article
- Angiopoietin-like protein 4 dysregulation in kidney diseases: a promising biomarker and therapeutic target.Frontiers in pharmacology · 2024Review
- The past, present, and future physiology and pharmacology of glucagon.Cell metabolism · 2022Review
- ANGPTL4: a multifunctional protein involved in metabolism and vascular homeostasis.Current opinion in hematology · 2020Review
- A Primary Role for α-Cells as Amino Acid Sensors.Diabetes · 2020Review
- ANGPTL4 in Metabolic and Cardiovascular Disease.Trends in molecular medicine · 2019Review
- Hepatokines-a novel group of exercise factors.Pflugers Archiv : European journal of physiology · 2019Review
- Deletion of the glucagon receptor gene before and after experimental diabetes reveals differential protection from hyperglycemia.Molecular metabolism · 2018Article
- Genetic inactivation of ANGPTL4 improves glucose homeostasis and is associated with reduced risk of diabetes.Nature communications · 2018Article
- Regulation of amino acid metabolism and α-cell proliferation by glucagon.Journal of diabetes investigation · 2018Review
- Interrupted Glucagon Signaling Reveals Hepatic α Cell Axis and Role for L-Glutamine in α Cell Proliferation.Cell metabolism · 2017Article
- Amino Acid Transporter Slc38a5 Controls Glucagon Receptor Inhibition-Induced Pancreatic α Cell Hyperplasia in Mice.Cell metabolism · 2017Article
- Glucagon antagonism in islet cell proliferation.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genetic disruption or pharmacologic inhibition of glucagon signaling effectively lowers blood glucose but results in compensatory glucagon hypersecretion involving expansion of pancreatic α-cell mass. Ben-Zvi et al. recently reported that angiopoietin-like protein 4 (Angptl4) links glucagon receptor inhibition to hyperglucagonemia and α-cell proliferation [Ben-Zvi et al. (2015)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.